Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207

Tsukada, Hiroko; Yokoyama, Akira; Goto, Kōichi; Shinkai, Tetsu; Harada, Masao; Ando, Masahiko; Shibata, Taro; Ohe, Yuichiro; Tamura, Tomohide; Saijo, Nagahiro

doi:10.1093/jjco/hyu176

Cited by 30 publications

(30 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, some studies report that the efficacy and toxicity of treatment with anticancer agents differ between the ages of 70 and 74 years and ≥75 years, and that elderly individuals should be defined as those aged ≥75 years [16,17]. In the present study, only 3 patients were aged ≤74 years, and 2 of them showed PD and received only one cycle of treatment.…”

Section: Discussionmentioning

confidence: 73%

A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer

et al. 2015

View full text Add to dashboard Cite

Background: S-1, a novel oral fluoropyrimidine, is active in the treatment of non-small cell lung cancer (NSCLC). However, data on S-1 for elderly patients with NSCLC are insufficient. Methods: Eligibility criteria were no prior chemotherapy, stage IIIB or IV NSCLC, performance status 0-1, age >70 years, and adequate hematological, hepatic, and renal functions. Patients received S-1 (40 mg/m² twice a day) for 28 consecutive days. This schedule was repeated every 6 weeks. The primary end point was the tumor response rate. Results: Thirty-two patients were enrolled and 31 patients were evaluable for response. The patients' median age was 80 years (range: 71-88). The response rate was 22.6% (95% CI: 11-38). Neutropenia, anemia, thrombocytopenia, febrile neutropenia, and diarrhea of grade ≥3 occurred in 6, 6, 10, 3, and 3%, respectively. Conclusions: In elderly patients with previously untreated advanced NSCLC, S-1 appears to be well tolerated and demonstrates encouraging activity.

show abstract

Section: Discussionmentioning

confidence: 73%

A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…However, treatment-related death was 4.4% for patients with NSCLC >70 years of age undergoing carboplatinbased doublet chemotherapy and remained a serious problem. On the other hand, in Japan, although there was a phase III trial that was designed to clarify whether the addition of cisplatin to monotherapy could improve survival for elderly patients, this study showed cisplatin-based doublet chemotherapy could not significantly associate with survival benefits in patients with NSCLC ≥ 75 years of age [18]. Moreover, elderly patients have been defined as patients aged ≥ 75 years in ongoing clinical trials, including in the JCOG1210/ WJOG7813L study (UMIN000011460) of docetaxel versus carboplatin plus pemetrexed followed by pemetrexed as a first-line treatment in elderly patients with advanced non-squamous NSCLC in Japan.…”

Section: Discussionmentioning

confidence: 86%

“…ORR of the second-line chemotherapy was 9.2% [95% confidence interval (CI), [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] in age ≥ 75 group and 12.2% (95% CI, 5-26) in age 70-74 group. There was no significance difference between the groups (p=0.75).…”

Section: Efficacymentioning

confidence: 99%

Effect of Second-Line Chemotherapy in Elderly Patients with Non-Small Cell Lung Cancer

Kobayashi¹,

Kenmotsu²,

Suzuki³

et al. 2017

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…In those patients ≥75 years of age, toxicity was higher without any OS benefit. 167 Another Japanese study compared the same weekly schedule of cisplatin and docetaxel with docetaxel alone administered every 3 weeks in chemotherapy-naive patients ≥70 years and PS 0-1. This study failed to demonstrate any advantage of the combination over single agent.…”

Section: Systemic Treatment In the Elderlymentioning

confidence: 99%

Extending Survival of Stage IV Non-Small Cell Lung Cancer

Carnio

Novello²,

Mele³

et al. 2014

Seminars in Oncology

View full text Add to dashboard Cite

Extending survival of stage IV non-small cell lung cancer. Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV. La versione definitiva è disponibile alla URL: http://www.sciencedirect.com/science/article/pii/S0093775413002236 Extending Survival of Stage IV Non-Small Cell Lung CancerCarnio S, Novello S, Mele T, Levra MG, Scagliotti GV.Most of patients with newly diagnosed non-small cell lung cancer (NSCLC) present with locally advanced or metastatic disease. In this setting the goal of treatment is to prolong survival and to control disease-and treatment-related symptoms. Currently systemic cytotoxic chemotherapy remains the first-line treatment for most patients with stage IV NSCLC, but preferred treatments are now defined by histology and based on the presence of specific molecular abnormalities. In firstline the combination of platinum plus pemetrexed with or without bevacizumab is a reasonable choice in patients with non-squamous NSCLC. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy are the recommended for patients with EGFRsensitizing mutations. A small-molecule TKI of anaplastic lymphoma kinase (ALK), crizotinib, showed pronounced clinical activity in the treatment of patients with NSCLC positive for EML4-ALK and it has rapidly entered into daily clinical practice. Currently no agents are specifically approved for the treatment of squamous cell carcinoma of the lung. Second-line treatments include docetaxel, pemetrexed, or erlotinib as single agents. There is a growing evidence that cytotoxics are better than EGFR-TKIs in EGFR wild-type patients. In the setting of the third line, the only approved agent is erlotinib. In elderly patients with good performance status (PS), doublet chemotherapy including platinum should not be excluded, especially for those patients 70-75 years of age without comorbidities. The better selection of patients, the identification of specific predictive biomarkers, a reasonable sequencing of all active and available treatments, including targeted therapies and cytotoxic, may significantly contribute to extend the natural history of stage IV NSCLC.Lung cancer remains a relevant health care problem and in the near future will account for almost 30% of all cancer-related deaths. Non-small cell lung cancer (NSCLC) represents more than 80% of all lung cancer cases. The majority of patients with lung cancer are diagnosed at baseline with locally advanced or metastatic disease. The increase in life expectancy with the associated cumulative increase in the risk of cancer has led to an increased incidence of this disease in the elderly population. Overall the incidence and death rates for lung cancer are decreasing for both men and women 1 ; however, the 5-year survival in stage IV NSCLC remains as low as 1%. 2According to the current World Health Organization (WHO) classification for lung tumors, NSCLC includes many histological subtypes, but for therapeutic purposes it can be broadly categorized as squamous and non-squamous. This non-canon...

show abstract

Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207

Cited by 30 publications

References 34 publications

A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer

A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer

Effect of Second-Line Chemotherapy in Elderly Patients with Non-Small Cell Lung Cancer

Extending Survival of Stage IV Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About